Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $126,719.91 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the sale, the director now owns 447,857 shares in the company, valued at $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Tyra Biosciences Trading Up 2.8 %

Shares of TYRA opened at $16.24 on Friday. Tyra Biosciences, Inc. has a 12 month low of $12.34 and a 12 month high of $29.60. The stock has a fifty day moving average price of $15.38 and a 200-day moving average price of $19.17. The firm has a market cap of $821.79 million, a PE ratio of -10.09 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Tyra Biosciences

Several institutional investors and hedge funds have recently modified their holdings of TYRA. JPMorgan Chase & Co. increased its stake in Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after buying an additional 3,896 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Tyra Biosciences during the 3rd quarter worth approximately $278,000. Barclays PLC increased its stake in Tyra Biosciences by 200.5% during the 3rd quarter. Barclays PLC now owns 37,625 shares of the company’s stock worth $884,000 after buying an additional 25,106 shares in the last quarter. State Street Corp increased its stake in Tyra Biosciences by 4.4% during the 3rd quarter. State Street Corp now owns 384,732 shares of the company’s stock worth $9,045,000 after buying an additional 16,248 shares in the last quarter. Finally, Polar Asset Management Partners Inc. purchased a new stake in Tyra Biosciences during the 3rd quarter worth approximately $2,071,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wedbush restated an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, January 13th. UBS Group assumed coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.